Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Shares Outstanding (Weighted Average) (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $171.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 20.1% to $171.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $171.6 million through Dec 2025, up 20.1% year-over-year, with the annual reading at $171.6 million for FY2025, 20.1% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $171.6 million at Relay Therapeutics, roughly flat from $172.4 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $172.4 million in Q3 2025, with the low at $90.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $126.4 million, with a median of $122.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 2071.45% in 2021, then grew 7.85% in 2024.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $95.1 million in 2021, then increased by 17.97% to $112.2 million in 2022, then rose by 9.22% to $122.6 million in 2023, then grew by 16.55% to $142.9 million in 2024, then increased by 20.1% to $171.6 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $171.6 million, $172.4 million, and $171.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.